GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intersect ENT Inc (NAS:XENT) » Definitions » Shares Outstanding (Basic Average)

Intersect ENT (Intersect ENT) Shares Outstanding (Basic Average) : 33.7 Mil (As of Mar. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Intersect ENT Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Intersect ENT's average basic shares outstanding for the quarter that ended in Mar. 2022 was 33.7 Mil.


Intersect ENT Shares Outstanding (Basic Average) Historical Data

The historical data trend for Intersect ENT's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intersect ENT Shares Outstanding (Basic Average) Chart

Intersect ENT Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.12 30.31 31.39 32.62 33.27

Intersect ENT Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.02 33.19 33.35 33.53 33.74

Intersect ENT Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Intersect ENT  (NAS:XENT) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Intersect ENT Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Intersect ENT's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Intersect ENT (Intersect ENT) Business Description

Traded in Other Exchanges
N/A
Address
1555 Adams Drive, Menlo Park, CA, USA, 94025
Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.
Executives
Elisabeth Sandoval director C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362
Neil A Hattangadi director 1555 ADAMS DRIVE MENLO PARK CA 94025
Reyna M Fernandez officer: Chief Human Resource Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Patrick A Broderick officer: EVP, GC & Corporate Secretary C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Thomas A. West director, officer: President and CEO C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Richard A Meier officer: EVP & Chief Financial Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Binney Robert H Jr officer: Vice President, Sales 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Susan P Stimson officer: Vice President, Marketing 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Lisa D Earnhardt director, officer: See Remarks 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Aaron Lehman officer: General Counsel C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeryl L Hilleman officer: Chief Financial Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Christine R Kowalski officer: Chief Operations Officer C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Richard E Kaufman officer: See Remarks 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Gwen R. Carscadden officer: Chief People Officer C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025